Abiopharma

🔍 Mehrotra Parth (Director)

Company: Privia Health Group, Inc. (PRVA)

Report Date: 2026-03-10

Detailed Transactions and Holdings:

• Sold 21,097 shares of Common Stock, $0.01 par value per share at $22.71 per share (Direct)
  Date: 2026-03-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 322,698.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 141,342 shares of Common Stock, $0.01 par value per share (Direct)
  Date: 2026-03-10 | Code: A | equity_swap_involved: 0 | shares_owned_after: 464,040.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 171,904 shares of Common Stock, $0.01 par value per share (Direct)
  Date: 2026-03-11 | Code: A | equity_swap_involved: 0 | shares_owned_after: 635,944.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person .
• F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.27 to $23.23 per share. The reporting person undertakes to provide to Privia Health Group, Inc., any security holder of Privia Health Group, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
• F3: Reflects restricted stock units under the 2021 Omnibus Incentive Plan that will vest in substantially equal annual installments on the first, second and third anniversaries of the grant date, generally subject to continued service throughout such dates.
• F4: Vesting and distribution to reporting person of 141,948 shares underlying performance stock units that were granted on May 9, 2023, and 29,956 shares underlying performance stock units that were granted on July 1, 2023, in both cases for the performance period 2023-2025.